Benzinga · Jun 24, 2026
GSK Commences Tender Offer To Acquire Nuvalent At $124/Share
https://www.londonstockexchange.com/news-article/GSK/gsk-announces-tender-offer-to-acquire-nuvalent/17655562
NU
NASDAQ · NUVL
Nuvalent, Inc.
Healthcare · Biotechnology
$123.96
Up+$0.00 (+0.00%)
Updated Sep 22, 2026, 11:00 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.69B
- P/E ratio
- -20.02
- Dividend yield
- 0.00%
- 52-week range
- $71.13 – $123.99
- Volume
- 3.07M
- Avg. volume
- 586K
Price performance
NUVL price history
1M range · 0 trading sessions · Daily adjusted prices
NUVL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NUVL news
The latest Smart Investors Daily articles mentioning NUVL.
Stock researchCompany · Overview
NUVL research
Overview
Company profile and research snapshot.
Company profile
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $133.09
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 24, 2026 | Bernstein | Market Perform | — |
| Jun 10, 2026 | TD Cowen | Hold | — |
| Jun 10, 2026 | Barclays | Equal-Weight | — |
| Jun 10, 2026 | Guggenheim | Neutral | — |
| Jun 10, 2026 | UBS | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Jun 24, 2026
Bernstein Downgrades Nuvalent to Market Perform, Lowers Price Target to $124
Bernstein analyst Jeffrey Walch downgrades Nuvalent (NASDAQ:NUVL) from Outperform to Market Perform and lowers the price target from $172 to $124.
Benzinga · Jun 12, 2026
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst takes on top stocks, sorted by accuracy.
SeekingAlpha · Jun 11, 2026
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors
Nuvalent (NUVL) analysis: GSKâs $10.6B buyout caps upside.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
